| Document |
Document Title |
|
WO/2016/105165A2 |
The present invention relates to a novel compound having excellent hole-injection, hole-transport and light-emitting capabilities and the like, and to an organic electroluminescent device which comprises the compound in at least one orga...
|
|
WO/2016/102039A1 |
The present invention relates to heterocyclic compounds and electronic devices, in particular organic electroluminescent devices, containing these compounds.
|
|
WO/2016/096778A1 |
This invention relates to novel benzazepine sulfonamide compounds of the formula (I), wherein R4 or R5 is -SO2-NR7R8 and R1 to R8 and Y are as defined in the description and in the claims, as well as pharmaceutically acceptable salts the...
|
|
WO/2016/094876A1 |
Methods and compositions for glial cell-derived neurotrophic factor (GDNF) induction in the eye, and for treatment and/or prevention of retinal disorders are described.
|
|
WO/2016/087370A1 |
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use...
|
|
WO/2016/079684A1 |
Process for the synthesis of benzazepine derivatives The invention relates to a process for the synthesis of 7,8-dimethoxy-1,3-dihydro- benzazepin-2-one of formula (II), as well as to a process for the synthesis of compound of formula (I).
|
|
WO/2016/068108A1 |
Disclosed is a method for selectively producing ε-caprolactam from a substance, as a raw material, which can be derived from biomass resources, through a short reaction step while inhibiting production of by-products, and without produc...
|
|
WO/2016/059942A1 |
Provided is a three-phase AC/DC conversion device disposed between a three-phase AC power supply and a light-emitting diode group, the device comprising: a three-phase full-bridge circuit in which pairs of switching elements are connecte...
|
|
WO/2016/055028A1 |
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....
|
|
WO/2016/051799A1 |
Provided is a tau aggregation inhibitor which is capable of sufficiently suppressing tau aggregation in cells. The present invention is a compound represented by formula (I) or a salt thereof. This compound is used for at least one appli...
|
|
WO/2016/046835A1 |
The invention relates to the compounds of formula I and formula laor its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of f...
|
|
WO/2016/039660A1 |
The present invention relates to medicine, and more particularly to pharmacology and psychiatry, and can be used in the manufacture of drugs for treating treatment-resistant forms of schizophrenia. To this end, it is proposed to use the ...
|
|
WO/2016/039141A1 |
A method for separating co-crystals, wherein co-crystals are supplied from the top of a crystal separation column, a solvent, which exhibits an incongruent dissolution system with respect to the co-crystals, or a solvent, which forms a e...
|
|
WO/2016/040225A1 |
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulato...
|
|
WO/2016/026172A1 |
Disclosed are an amorphous ivabradine hydrochloride, and a preparation method therefor and uses thereof. The method for preparing the ivabradine hydrochloride comprises the following steps: dissolving ivabradine hydrochloride in water to...
|
|
WO/2016/009314A1 |
Subject-matter of the present invention is a novel amorphous compound comprising ivabradine, in particular a solid amorphous compound consisting of ivabradine and chrysin. Subject-matter of the invention is also a process for the prepara...
|
|
WO/2016/004911A1 |
The present invention relates to a new solid form of ivabradine hydrochloride and (R)-mandelic acid of formula (II) hi the molar ratio of 1:1. The method of preparing the above mentioned cocrystal consists in mixing or grinding the indiv...
|
|
WO/2015/185990A1 |
This invention relates to medicine, and more particularly to methods for producing double salts of (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1Н-3-benzazepine (lorcaserin), the products of said methods and compositions for the treatment ...
|
|
WO/2015/175528A1 |
Provided herein are methods of producing compounds, such as cyclohexanone, hexanediamine, hexanediol, hexamethylenediamine, caprolactam and nylon, from 5- (halomethyl)furfural.
|
|
WO/2015/170346A1 |
The present invention discloses a process for synthesis of Lorcaserin and its analogues using epoxide/chiral epoxide.
|
|
WO/2015/170053A1 |
The invention relates to a hemipamoate of ivabradine with formula (I): and to the hydrates thereof. The invention also relates to drugs.
|
|
WO/2015/161730A1 |
The present invention relates to a new type of eutectic crystal of lorcaserin hydrochloride and benzoic acid. Compared with the prior art, the eutectic crystal has the improved properties of good stability, low solubility, and being suit...
|
|
WO/2015/153683A1 |
This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses me...
|
|
WO/2015/146053A1 |
Provided are: a non-ionic photoacid generator including an imide sulfonate compound and having high light sensitivity to an i-line, excellent thermal stability, and excellent solubility in a hydrophobic material; and a resin composition ...
|
|
WO/2015/143692A1 |
Compounds of Formula I and their uses of effective AXL inhibitors and for the treatment of physical condition mediated by AXL.
|
|
WO/2015/148480A1 |
Rett syndrome (RTT), a childhood neurological disorder that affects primarily females, may be treated by use of a galanthamine analog wherein the hydroxy group of galantamine is replaced by a carbamate, carbonate or ester group and the m...
|
|
WO/2015/142346A1 |
Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.
|
|
WO/2015/138496A1 |
Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazin...
|
|
WO/2015/106636A1 |
A demethylivabradine salt, and a preparation method therefor and uses thereof. The demethylivabradine salt is a pharmaceutically acceptable salt, and the pharmaceutically acceptable salt comprises citrate, hydrobromide, sulfate, phosphat...
|
|
WO/2015/109130A1 |
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.
|
|
WO/2015/102017A1 |
The present invention relates to stable crystalline Form I of Iorcaserin hydrochloride of Formula (IA) and processes for its preparation. The invention also relates to processes for the preparation of lorcaserin and pharmaceutically acce...
|
|
WO/2015/101072A1 |
Disclosed are a new S crystal form of Ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof. The powder diffraction spectrum of the S crystal form of Ivabradine hydrochloride has characteristic peaks whe...
|
|
WO/2015/097071A1 |
The present invention relates to haloalkylsulphonamide derivatives of the formula (1): wherein A represents -CH=CH- or a sulphur atom, W represents an oxygen atom or the like, R1 represents C1-C6 haloalkyl, R2, R3 and R4 each independent...
|
|
WO/2015/096119A1 |
Disclosed in the present application are the following crystals of Lorcaserin: sulfamate, stearate, cholate, 4-aminobenzene sulfonate, or terephthalate, and the preparation methods and pharmaceutical compositions thereof, and the uses th...
|
|
WO/2015/077344A1 |
In one aspect, cobalt complexes are described herein. In some embodiments, such cobalt complexes are operable as catalysts for hydroboration and borylation applications.
|
|
WO/2015/067604A1 |
The present invention providesstabilized amorphous lorcaserin hydrochloride ((R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]- azepinehydrochloride), a pharmaceutical composition comprising the same, as well as a process for obtainin...
|
|
WO/2015/062189A1 |
The present invention relates to a method and apparatus for recovering caprolactam in benzene distillation residue, and provides a method for recovering caprolactam in benzene distillation residue, comprising the following steps: (a) sep...
|
|
WO/2015/048937A1 |
The present invention relates to a new solid form of ivabradine hydrochloride and (S)- mandelic acid of formula II in the molar ratio of 1:1. The method for the preparation of the above mentioned cocrystal consists in mixing or grinding ...
|
|
WO/2015/034820A1 |
Disclosed are compounds of Formula (I): (I). Also disclosed are methods of using such compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowin...
|
|
WO/2015/010885A1 |
Present application discloses an industrial scale continuous process for recovery of caprolactam and crystalline ammonium sulfate. By controlling the weight ratio of the amount of aqueous ammonium sulfate solution being recycled to the a...
|
|
WO/2015/007897A1 |
The present invention provides a very simple, efficient and economic technology for racemisation of amines, alcohols or thioalcohols where the chiral carbon (benzylic position) is located at the β-position of the heteroatom (amino, hydr...
|
|
WO/2014/202765A1 |
The present invention provides an asymmetric and economic synthesis of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1 H-benzo[d]azepine via novel intermediates applying an asymmetric enzymatic, biomimetic or catalytic reduction. The present inve...
|
|
WO/2014/199645A1 |
The purpose of the present invention is to provide a pharmaceutical composition that is useful for the treatment of diseases that are caused by an increase in bone resorption and that does not cause serious side effects even when used in...
|
|
WO/2014/188783A1 |
The purpose of the invention is to provide a production method that makes possible the industrial production of an optically active α-amino acid at high yield and high enantioselectivity, to provide a simple method for producing optical...
|
|
WO/2014/188248A1 |
The invention refers to a process for preparing ivabradine, in particular a process for preparing an ivabradine salt.
|
|
WO/2014/187768A1 |
The present invention is directed to a short, facile, effective and industrially applicable process for obtaining 8-chloro-l-methyl-2,3,4,5-tetrahydro-lH- benzo[d]azepine, or its salt, preferably lorcaserin hydrochloride. The present inv...
|
|
WO/2014/184501A1 |
The invention relates to a method for the synthesis of a compound of the formula (I), to the use thereof for the synthesis of ivabradine, of the addition salts thereof to a pharmaceutically acceptable acid, and the hydrates thereof.
|
|
WO/2014/174745A1 |
Compared to a traditional Eg5 (KSP: kinesin spindle protein) inhibitor, this water-soluble polycyclic compound or a pharmacologically acceptable salt thereof has a greater solubility in an aqueous solvent and has Eg5 inhibitory activity ...
|
|
WO/2014/173928A1 |
The present invention is directed to a simple and economical process for the preparation of 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine via novel intermediates and a highly selective asymmetric synthesis leading to enantiopur...
|
|
WO/2014/154682A1 |
The present invention relates to a series of novel compounds, methods to prevent or treat viral infections in animals by using the novel compounds and to said novel compounds for use as a medicine, more preferably for use as a medicine t...
|
